GC Cell Corporation

Equities

A144510

KR7144510005

Healthcare Facilities & Services

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
37,600 ^KRW	+0.53%		+4.16%	-17.36%

Feb. 26	GC Cell and Biocentriq® Execute Process Transfer Agreement in Anticipation of the U.S. Entry of Immuncell-LC Inj	CI
Jan. 08	GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform	CI

GC Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 03:48 am EDT

GC Cell Corporation reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 279.87 million compared to negative sales of KRW 0.00009 million a year ago. Net loss was KRW 2,842.15 million compared to net income of KRW 24,640.83 million a year ago.

Basic loss per share from continuing operations was KRW 189 compared to basic earnings per share from continuing operations of KRW 1,641 a year ago. Diluted loss per share from continuing operations was KRW 190 compared to diluted earnings per share from continuing operations of KRW 1,637 a year ago. Basic loss per share was KRW 189 compared to basic earnings per share of KRW 1,641 a year ago.

Diluted loss per share was KRW 190 compared to diluted earnings per share of KRW 1,637 a year ago.

Latest news about GC Cell Corporation

GC Cell and Biocentriq® Execute Process Transfer Agreement in Anticipation of the U.S. Entry of Immuncell-LC Inj	Feb. 26	CI
GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform	Jan. 08	CI
GC Cell Affiliate BioCentriq Secures $29 Million in Funding Round	Jan. 08	MT
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment	Dec. 26	MT
GC Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
GC Cell Obtains Anti-Bribery Management System Certification from Korea Compliance Initiative	23-04-06	CI
GC Cell Inks First Licensing Agreement for Immuncell-LC® With Rivaara Immune Private Limited in India	22-01-03	CI
Green Cross Lab Cell Corporation completed the acquisition of Green Cross Cell Corporation from a group of shareholders.	21-10-26	CI
Green Cross Lab Cell Corporation entered into a definitive merger agreement to acquire Green Cross Cell Corporation from a group of shareholders for approximately KRW 510 billion.	21-07-15	CI
Artiva Biotherapeutics, Inc. announced that it has received $120.000001 million in funding from a group of investors	21-02-25	CI
Artiva Biotherapeutics, Inc. announced that it expects to receive $120.000001 million in funding	21-02-18	CI
Artiva Biotherapeutics, Inc. announced that it expects to receive $80.552315 million in funding from 5AM Venture Management, LLC, venBio LLC, RA Capital Management, L.P., Medivate Partners LLC, Green Cross Holdings Corporation, Green Cross Lab Cell Corporation	20-06-24	CI
Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell to Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy	20-03-31	CI
Green Cross LabCell and Feldan Therapeutics Announce a Joint Research Collaboration to Develop Low Immunogenicity, High-Performance Natural Killer Anticancer Treatment	18-01-15	CI
Green Cross Lab Cell Corporation Announces Executive Changes	17-03-26	CI
Green Cross Lab Cell Corporation(KOSDAQ:A144510) added to S&P Global BMI Index	16-09-19	CI
GreenCross LabCell Corporation has completed an IPO in the amount of KRW 37.00 billion.	16-06-22	CI
Oxford BioMedica plc Enters into Research & Development Collaboration with Green Cross LabCell	16-06-02	CI
GreenCross LabCell Corporation has filed an IPO.	16-03-04	CI

Chart GC Cell Corporation

Duration

Period

More charts

Company Profile

GC Cell Corp formerly Green Cross Lab Cell Corp is a Korea-based company principally engaged in the provision of specimen testing services. The Company operates its business through four segments. The Specimen Testing Service segment provides sample testing services, clinical trial services, and veterinary testing services. The Cell Therapy segment is engaged in cell culture and technology transfer business. The Cord Blood Storage segment is engaged in the cord blood storage business. The Other Business segment is engaged in bio-logistics business and others.

Sector

Healthcare Facilities & Services

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
GC CELL CORPORATION	-17.36%	410M
SONIC HEALTHCARE LIMITED	-17.89%	8.25B
RADNET, INC.	+39.20%	3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
NEOGENOMICS, INC.	-12.61%	1.81B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B

Medical & Diagnostic Laboratories